Switch to:
Also traded in: Denmark, Germany, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 21.80
NVO's Cash to Debt is ranked lower than
55% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. NVO: 21.80 )
Ranked among companies with meaningful Cash to Debt only.
NVO' s Cash to Debt Range Over the Past 10 Years
Min: 0.29  Med: 11.99 Max: N/A
Current: 21.8
Equity to Asset 0.45
NVO's Equity to Asset is ranked lower than
76% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. NVO: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
NVO' s Equity to Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.65 Max: 0.73
Current: 0.45
0.42
0.73
F-Score: 7
Z-Score: 16.12
M-Score: -2.42
WACC vs ROIC
12.19%
141.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 43.57
NVO's Operating margin (%) is ranked higher than
95% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. NVO: 43.57 )
Ranked among companies with meaningful Operating margin (%) only.
NVO' s Operating margin (%) Range Over the Past 10 Years
Min: 21.38  Med: 32.40 Max: 45.81
Current: 43.57
21.38
45.81
Net-margin (%) 31.33
NVO's Net-margin (%) is ranked higher than
93% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. NVO: 31.33 )
Ranked among companies with meaningful Net-margin (%) only.
NVO' s Net-margin (%) Range Over the Past 10 Years
Min: 16.65  Med: 24.74 Max: 32.3
Current: 31.33
16.65
32.3
ROE (%) 86.71
NVO's ROE (%) is ranked higher than
99% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. NVO: 86.71 )
Ranked among companies with meaningful ROE (%) only.
NVO' s ROE (%) Range Over the Past 10 Years
Min: 22.36  Med: 42.79 Max: 79.9
Current: 86.71
22.36
79.9
ROA (%) 41.18
NVO's ROA (%) is ranked higher than
98% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. NVO: 41.18 )
Ranked among companies with meaningful ROA (%) only.
NVO' s ROA (%) Range Over the Past 10 Years
Min: 14.9  Med: 25.96 Max: 41.29
Current: 41.18
14.9
41.29
ROC (Joel Greenblatt) (%) 170.39
NVO's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. NVO: 170.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 36.68  Med: 87.93 Max: 178.92
Current: 170.39
36.68
178.92
Revenue Growth (3Y)(%) 14.00
NVO's Revenue Growth (3Y)(%) is ranked higher than
69% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. NVO: 14.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 7.1  Med: 13.20 Max: 18.7
Current: 14
7.1
18.7
EBITDA Growth (3Y)(%) 15.50
NVO's EBITDA Growth (3Y)(%) is ranked higher than
71% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. NVO: 15.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 9.6  Med: 15.50 Max: 25.7
Current: 15.5
9.6
25.7
EPS Growth (3Y)(%) 20.30
NVO's EPS Growth (3Y)(%) is ranked higher than
76% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. NVO: 20.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 10.2  Med: 20.30 Max: 29.7
Current: 20.3
10.2
29.7
» NVO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

NVO Guru Trades in Q2 2015

Tom Gayner 1,075,000 sh (unchged)
Murray Stahl 7,740 sh (unchged)
Ruane Cunniff 81,800 sh (-0.30%)
Mario Gabelli 6,545 sh (-2.31%)
Ken Fisher 12,295,864 sh (-2.88%)
Jim Simons 14,087,000 sh (-2.94%)
» More
Q3 2015

NVO Guru Trades in Q3 2015

Murray Stahl 7,827 sh (+1.12%)
Tom Gayner 1,075,000 sh (unchged)
Ruane Cunniff 81,320 sh (-0.59%)
Ken Fisher 11,652,268 sh (-5.23%)
Mario Gabelli 6,170 sh (-5.73%)
Jim Simons 13,171,000 sh (-6.50%)
» More
Q4 2015

NVO Guru Trades in Q4 2015

Mario Gabelli 6,210 sh (+0.65%)
Ruane Cunniff 81,320 sh (unchged)
Tom Gayner 1,075,000 sh (unchged)
Murray Stahl 7,827 sh (unchged)
Spiros Segalas 7,362,676 sh (unchged)
Ken Fisher 11,447,413 sh (-1.76%)
Jim Simons 12,898,800 sh (-2.07%)
» More
Q1 2016

NVO Guru Trades in Q1 2016

Jeremy Grantham 122,600 sh (New)
Ruane Cunniff 97,525 sh (+19.93%)
Mario Gabelli 6,225 sh (+0.24%)
Tom Gayner 1,075,000 sh (unchged)
Murray Stahl 7,787 sh (-0.51%)
Jim Simons 12,775,700 sh (-0.95%)
Ken Fisher 11,178,809 sh (-2.35%)
Spiros Segalas 6,179,837 sh (-16.07%)
» More
» Details

Insider Trades

Latest Guru Trades with NVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, NAS:AMGN, NAS:GILD, NAS:CELG, NAS:BIIB » details
Traded in other countries:NOVO B.Denmark, NOVA.Germany, NOVOB.Switzerland, 0QIU.UK, NONOF.USA,
Novo-Nordisk A/S is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company has two business segments: diabetes care and biopharmaceuticals.

Novo-Nordisk A/S is a healthcare company incorporated on November 28, 1931 in Denmark. The Company has diabetes product portfolios, including new generation insulins, a full portfolio of modern insulins as well as a human once-daily GLP-1 analog. In addition, it also has a position within haemophilia care, growth hormone therapy and hormone replacement therapy, and Company's first product to treat obesity, Saxenda, was approved in the United States in December 2014. The Company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments: diabetes care and biopharmaceuticals. The diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. On December 23, 2014, the GLP-1 agonist liraglutide was approved in the United States in a 3 mg dose for weight management. The trade name for this product will be Saxenda and launch is planned for the first half of 2015. The biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. In 2014 the Company announced that all activities within inflammation will be discontinued. The Company's insulin and other pharmaceutical products are marketed and distributed through subsidiaries, distributors and independent agents with responsibility for specific geographical areas. The important markets are North America, China, Japan and the major European countries. In addition there is an increasing contribution to its total sales from key markets in the sales region International Operations such as Algeria, Turkey, Australia, India, Argentina, Brazil and Russia.

Ratios

vs
industry
vs
history
P/E(ttm) 26.64
NVO's P/E(ttm) is ranked higher than
56% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 29.15 vs. NVO: 26.64 )
Ranked among companies with meaningful P/E(ttm) only.
NVO' s P/E(ttm) Range Over the Past 10 Years
Min: 12.13  Med: 24.05 Max: 35.76
Current: 26.64
12.13
35.76
Forward P/E 21.14
NVO's Forward P/E is ranked lower than
59% of the 94 Companies
in the Global Biotechnology industry.

( Industry Median: 17.15 vs. NVO: 21.14 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 26.64
NVO's PE(NRI) is ranked higher than
56% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 30.43 vs. NVO: 26.64 )
Ranked among companies with meaningful PE(NRI) only.
NVO' s PE(NRI) Range Over the Past 10 Years
Min: 12.03  Med: 24.05 Max: 35.76
Current: 26.64
12.03
35.76
Price/Owner Earnings (ttm) 29.93
NVO's Price/Owner Earnings (ttm) is ranked higher than
55% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 37.01 vs. NVO: 29.93 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
NVO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 13.81  Med: 29.46 Max: 68.66
Current: 29.93
13.81
68.66
P/B 24.97
NVO's P/B is ranked lower than
95% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. NVO: 24.97 )
Ranked among companies with meaningful P/B only.
NVO' s P/B Range Over the Past 10 Years
Min: 3.66  Med: 7.98 Max: 31.9
Current: 24.97
3.66
31.9
P/S 8.39
NVO's P/S is ranked higher than
60% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. NVO: 8.39 )
Ranked among companies with meaningful P/S only.
NVO' s P/S Range Over the Past 10 Years
Min: 2.8  Med: 5.86 Max: 11.01
Current: 8.39
2.8
11.01
PFCF 26.48
NVO's PFCF is ranked higher than
51% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 26.95 vs. NVO: 26.48 )
Ranked among companies with meaningful PFCF only.
NVO' s PFCF Range Over the Past 10 Years
Min: 12.07  Med: 24.38 Max: 47.08
Current: 26.48
12.07
47.08
POCF 22.20
NVO's POCF is ranked higher than
54% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. NVO: 22.20 )
Ranked among companies with meaningful POCF only.
NVO' s POCF Range Over the Past 10 Years
Min: 9.91  Med: 19.45 Max: 32.54
Current: 22.2
9.91
32.54
EV-to-EBIT 22.11
NVO's EV-to-EBIT is ranked higher than
53% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 24.27 vs. NVO: 22.11 )
Ranked among companies with meaningful EV-to-EBIT only.
NVO' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.2  Med: 16.90 Max: 25.7
Current: 22.11
9.2
25.7
EV-to-EBITDA 20.66
NVO's EV-to-EBITDA is ranked higher than
51% of the 304 Companies
in the Global Biotechnology industry.

( Industry Median: 21.30 vs. NVO: 20.66 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.2  Med: 16.40 Max: 25.1
Current: 20.66
8.2
25.1
PEG 1.42
NVO's PEG is ranked higher than
69% of the 93 Companies
in the Global Biotechnology industry.

( Industry Median: 2.28 vs. NVO: 1.42 )
Ranked among companies with meaningful PEG only.
NVO' s PEG Range Over the Past 10 Years
Min: 0.48  Med: 1.24 Max: 5.17
Current: 1.42
0.48
5.17
Shiller P/E 50.99
NVO's Shiller P/E is ranked higher than
51% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 51.13 vs. NVO: 50.99 )
Ranked among companies with meaningful Shiller P/E only.
NVO' s Shiller P/E Range Over the Past 10 Years
Min: 22.91  Med: 42.89 Max: 67.81
Current: 50.99
22.91
67.81
Current Ratio 1.13
NVO's Current Ratio is ranked lower than
87% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. NVO: 1.13 )
Ranked among companies with meaningful Current Ratio only.
NVO' s Current Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.99 Max: 2.45
Current: 1.13
1.04
2.45
Quick Ratio 0.81
NVO's Quick Ratio is ranked lower than
88% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. NVO: 0.81 )
Ranked among companies with meaningful Quick Ratio only.
NVO' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.32 Max: 1.91
Current: 0.81
0.74
1.91
Days Inventory 280.69
NVO's Days Inventory is ranked lower than
83% of the 446 Companies
in the Global Biotechnology industry.

( Industry Median: 127.50 vs. NVO: 280.69 )
Ranked among companies with meaningful Days Inventory only.
NVO' s Days Inventory Range Over the Past 10 Years
Min: 246.45  Med: 292.48 Max: 343.56
Current: 280.69
246.45
343.56
Days Sales Outstanding 54.79
NVO's Days Sales Outstanding is ranked higher than
57% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. NVO: 54.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.09  Med: 51.24 Max: 53.6
Current: 54.79
45.09
53.6
Days Payable 82.49
NVO's Days Payable is ranked higher than
62% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 58.35 vs. NVO: 82.49 )
Ranked among companies with meaningful Days Payable only.
NVO' s Days Payable Range Over the Past 10 Years
Min: 65.17  Med: 93.12 Max: 124.07
Current: 82.49
65.17
124.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.79
NVO's Dividend Yield is ranked higher than
68% of the 206 Companies
in the Global Biotechnology industry.

( Industry Median: 1.23 vs. NVO: 1.79 )
Ranked among companies with meaningful Dividend Yield only.
NVO' s Dividend Yield Range Over the Past 10 Years
Min: 0.79  Med: 1.51 Max: 2.47
Current: 1.79
0.79
2.47
Dividend Payout 0.47
NVO's Dividend Payout is ranked lower than
71% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. NVO: 0.47 )
Ranked among companies with meaningful Dividend Payout only.
NVO' s Dividend Payout Range Over the Past 10 Years
Min: 0.5  Med: 1.30 Max: 1.85
Current: 0.47
0.5
1.85
Dividend Growth (3y) 21.30
NVO's Dividend Growth (3y) is ranked higher than
80% of the 90 Companies
in the Global Biotechnology industry.

( Industry Median: 6.30 vs. NVO: 21.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
NVO' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 22.70 Max: 49.4
Current: 21.3
0
49.4
Forward Dividend Yield 1.78
NVO's Forward Dividend Yield is ranked higher than
64% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 1.34 vs. NVO: 1.78 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 9.02
NVO's Yield on cost (5-Year) is ranked higher than
95% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 1.53 vs. NVO: 9.02 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVO' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.98  Med: 7.61 Max: 12.45
Current: 9.02
3.98
12.45
3-Year Average Share Buyback Ratio -3.10
NVO's 3-Year Average Share Buyback Ratio is ranked higher than
76% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. NVO: -3.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.1  Med: 1.50 Max: 8
Current: -3.1
-3.1
8

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 672.00
NVO's Price/Net Current Asset Value is ranked lower than
100% of the 783 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. NVO: 672.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NVO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 11.62  Med: 24.52 Max: 710.4
Current: 672
11.62
710.4
Price/Tangible Book 26.48
NVO's Price/Tangible Book is ranked lower than
93% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. NVO: 26.48 )
Ranked among companies with meaningful Price/Tangible Book only.
NVO' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.14  Med: 6.79 Max: 31.52
Current: 26.48
3.14
31.52
Price/Projected FCF 3.77
NVO's Price/Projected FCF is ranked higher than
51% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. NVO: 3.77 )
Ranked among companies with meaningful Price/Projected FCF only.
NVO' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.41  Med: 2.95 Max: 82.77
Current: 3.77
1.41
82.77
Price/DCF (Earnings Based) 0.94
NVO's Price/DCF (Earnings Based) is ranked higher than
71% of the 17 Companies
in the Global Biotechnology industry.

( Industry Median: 1.23 vs. NVO: 0.94 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.44
NVO's Price/Median PS Value is ranked lower than
76% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. NVO: 1.44 )
Ranked among companies with meaningful Price/Median PS Value only.
NVO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 0.82 Max: 1.78
Current: 1.44
0.13
1.78
Price/Peter Lynch Fair Value 1.07
NVO's Price/Peter Lynch Fair Value is ranked higher than
72% of the 60 Companies
in the Global Biotechnology industry.

( Industry Median: 1.68 vs. NVO: 1.07 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
NVO' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.19  Med: 1.12 Max: 3.78
Current: 1.07
0.19
3.78
Price/Graham Number 5.60
NVO's Price/Graham Number is ranked lower than
74% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 3.11 vs. NVO: 5.60 )
Ranked among companies with meaningful Price/Graham Number only.
NVO' s Price/Graham Number Range Over the Past 10 Years
Min: 1.58  Med: 2.62 Max: 6.76
Current: 5.6
1.58
6.76
Earnings Yield (Greenblatt) (%) 4.51
NVO's Earnings Yield (Greenblatt) (%) is ranked higher than
88% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. NVO: 4.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.9  Med: 5.90 Max: 10.8
Current: 4.51
3.9
10.8
Forward Rate of Return (Yacktman) (%) 29.09
NVO's Forward Rate of Return (Yacktman) (%) is ranked higher than
76% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 14.18 vs. NVO: 29.09 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 7.5  Med: 23.20 Max: 38.6
Current: 29.09
7.5
38.6

More Statistics

Revenue (TTM) (Mil) $16,380
EPS (TTM) $ 2.00
Beta0.39
Short Percentage of Float0.11%
52-Week Range $46.17 - 60.34
Shares Outstanding (Mil)2,600.00

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 19,578 20,631 22,222
EPS($) 2.61 2.88 3.14
EPS without NRI($) 2.61 2.88 3.14
» More Articles for NYSE:NVO

Headlines

Articles On GuruFocus.com
Jim Simons' Top Holdings Include VeriSign, Chipotle Dec 15 2015 
Value Investing in BioPharma Nov 18 2015 
Jim Simons' Five Most-Heavily Weighted Holdings Oct 21 2015 
Ken Fisher Reduces Stake in Toyota, Increases Position in Anheuser-Busch Oct 20 2015 
Jim Simons and Ken Fisher Decrease Exposure on Novo Nordisk A/S Sep 14 2015 
Nintai Returns: Q2 2015 Jul 01 2015 
Leith Wheeler Investment Funds First Quarter 2015 Review Jun 15 2015 
Jim Simons' Top 3 Positions and One That Doubled Return Jun 10 2015 
Weekly 52-Week Highs Highlight: ALTR, AIG, LUX, NVO, EXPE May 03 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 

More From Other Websites
Sanofi Is Shuffling Its Exec Roster Amid Continued Struggles May 23 2016
FDA staff question usefulness of Sanofi diabetes drugs May 23 2016
FDA staff question usefulness of Sanofi diabetes drugs May 23 2016
FDA Staff Questions Usefulness of Sanofi’s Diabetes Drug Combo May 23 2016
FDA staff question utility, trials of Novo Nordisk diabetes drug May 20 2016
FDA staff question utility, trials of Novo Nordisk diabetes drug May 20 2016
FDA posts briefing materials prior to Advisory Committee meeting for IDegLira, a fixed combination... May 20 2016
FDA staff question utility of Novo Nordisk combo diabetes drug May 20 2016
FDA staff question utility of Novo Nordisk combo diabetes drug May 20 2016
Novo Nordisk A/S - Share repurchase programme May 19 2016
Renaissance Technologies Bullish on PepsiCo (PEP) and Gold Heading Into Q2 May 18 2016
Novo Nordisk files for regulatory approval in the US of long-acting factor IX for the treatment of... May 16 2016
Emisphere Reports First Quarter 2016 Financial Results May 16 2016
Emisphere Reports First Quarter 2016 Financial Results May 16 2016
We're Focused on What We're Good At, Says Nordisk CEO May 13 2016
We're Focused on What We're Good At, Says Nordisk CEO May 13 2016
Trading in Novo Nordisk shares by board members, executives and associated persons on 12 May 2016 May 13 2016
ETF’s with exposure to Novo Nordisk A/S : May 11, 2016 May 11 2016
Novo Nordisk A/S :NVO-US: Earnings Analysis: Q1, 2016 By the Numbers May 10 2016
Will Novo’s Modern Insulin Portfolio Fall Soon? May 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)